Core Insights - The company is transitioning from traditional wild harvesting of the medicinal herb "Guo Sui Bu" to a technology-driven cultivation model, marking a significant shift in its operational strategy [1][2] - The company has established a partnership with the Chinese Academy of Sciences to develop key cultivation technologies, which are essential for the industrialization of "Guo Sui Bu" [1] - The company has achieved significant growth, with projected production value exceeding 1.12 billion yuan in 2024, and sales of over 500 tons generating more than 30 million yuan in revenue last year [2] Company Developments - Since 2018, the company has built a 6,700 square meter intelligent seedling greenhouse and over 200 acres of planting base, along with developing the first dedicated drying and depilation production line for "Guo Sui Bu" in the country [2] - The company has established long-term supply relationships with 12 pharmaceutical companies, including Beijing Qihuang Pharmaceutical and Tongrentang [2] - The company was recognized as a key leading enterprise in agricultural industrialization in Guizhou Province in 2023 [2] Industry Trends - The total available forest land in Kaili City is 360,000 acres, indicating a trend towards large-scale development of the "Guo Sui Bu" industry [2] - The local forestry department plans to expand the planting area to 5,000 acres within three years by promoting land transfer and project applications [2]

Core Viewpoint - The National Pharmacopoeia Commission has published 11 draft standards for the processing of traditional Chinese medicine (TCM) decoction pieces, addressing quality issues that have arisen this year due to frequent non-compliance in drug inspections [1][2]. Group 1: Draft Standards for TCM Decoction Pieces - The 11 draft standards cover various TCM decoction pieces including Banbianlian, Zisuye, Beishashen, Guanghuoxiang, Yimucao, Gaoliangjiang, Shudihuang, Shichangpu, Jingjie, Qicaotan, and Qicaoshan, specifying guidelines for processing, characteristics, and storage [2]. - For example, the processing standard for Banbianlian includes removing impurities, washing, cutting, drying, and sieving, while its characteristics and storage requirements are also detailed [2]. Group 2: Quality Inspection Reports - Multiple regions have reported non-compliance in TCM decoction pieces during drug quality inspections, with notable failures in Shanxi Province where 6 batches of decoction pieces were found non-compliant, involving well-known companies [3]. - In Jiangxi Province, 18 products were reported as non-compliant, including 11 batches of TCM materials and decoction pieces, with issues related to characteristics, identification, and microbial limits [4]. Group 3: Regulatory Actions and Expert Insights - Regulatory bodies are intensifying scrutiny on TCM decoction pieces, as evidenced by significant fines imposed on companies for producing substandard products, such as Anhui Baicui Jinfang Pharmaceutical Co., which faced penalties totaling 3.11 million yuan [4]. - Experts attribute the prevalence of substandard TCM decoction pieces to various factors, including the complexity of sourcing raw materials, lack of professional knowledge among suppliers, and the challenges of standardizing production practices [5][6].